Loading...
ROCO
4163
Market cap215mUSD
Oct 08, Last price  
135.50TWD
1D
1.12%
1Q
6.27%
Jan 2017
7.86%
IPO
33.30%
Name

Intai Technology Corp

Chart & performance

D1W1MN
ROCO:4163 chart
P/E
27.51
P/S
2.86
EPS
4.93
Div yield, %
2.58%
Shrs. gr., 5y
-0.81%
Rev. gr., 5y
4.17%
Revenues
2.41b
+1.22%
2,327,239,0001,961,112,0001,973,345,0002,413,462,0002,444,688,0002,376,219,0002,405,149,000
Net income
250m
-3.96%
363,981,000246,838,000228,438,000422,331,000340,582,000259,892,000249,599,000
CFO
472m
+71.86%
0306,656,00061,026,000426,290,000579,479,000274,577,000471,901,000
Dividend
Mar 23, 20263.5 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

INTAI Technology Corporation, established in 1988 and headquartered in Taichung, Taiwan, is a diversified manufacturer. The company specializes in providing a broad spectrum of products to various sectors, including automotive, aerospace, precision hardware, medical devices, and electronic communication, serving both the Taiwanese domestic market and international clients. Its extensive product portfolio features both standard and custom-engineered precision hardware components. INTAI also dedicates a significant portion of its expertise to the medical field, manufacturing critical components for applications like endoscopic minimally invasive surgery, breast biopsy devices, and a wide array of disposable and reusable medical instruments. Furthermore, the company develops and supplies a comprehensive range of orthopedic implants, such as thoracolumbar and cervical spinal sets, pedicle screws, PEEK and titanium cages, trauma screws and plates, and specialized surgical instruments. Beyond these, INTAI extends its capabilities to offer RF and microwave products, catering to commercial, wireless, automotive, and telecommunication industries.

Key people

Chun-Nan Lin
General Manager, Director · since 2020
Deputy General Manager-Microwave Switch Business Division · since 2022
Menghui Lin
Deputy General Manager-Fastener Business Division · since 2024
Jinxiang Wang
Deputy General Manager-Medical Business Division · since 2024
Yaling Chen
Head of Finance & Accounting, Corporate Governance Officer · since 2024
Xiaoyong Chen
Director · since 2020
Baozhang Lin
Chief Strategy Officer, Director · since 2011
Zhaoxun Zhong
Chairman of the Board, Chief Technology Officer · since 2024
Cheng-Hsiung Pan
Independent Director · since 2020
Independent Director · since 2020
Independent Director · since 2014
IPO date
Oct 24, 2011
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT